Compare Indonesia Energy Corporation Limited (INDO) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Inovio Pharmaceuticals Inc — how do they compare? Indonesia Energy Corporation Limited trades at $2.74 (market cap $43.24M), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Inovio Pharmaceuticals Inc is far larger — about 2.6× Indonesia Energy Corporation Limited's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| INDO | INO | |
|---|---|---|
Market Cap | $43.24M | $112.19M |
Volume | 116,953 | 3,201,278 |
Sector | Energy | Health |
52-Week High | $6.74 | $2.65 |
52-Week Low | $2.49 | $0.66 |
Typical Hold Time | 24 Days | 43 Days |
Enterprise Value | $38.18M | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.74, down 1.08% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $5.10 million on $2.01 million revenue in 2025, with negative profit margins and cash flow from operations. Recent news highlights progress on the K-29 well drilling and upcoming investor presentations.
Despite a 100% buy rating from 3 analysts, INDO faces significant financial challenges with persistent losses and negative cash flow. The stock's outlook hinges on successful production from new wells, but execution risks and weak fundamentals present substantial downside potential for investors.
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
